JP4324812B2 - メロキシカムの精製方法 - Google Patents
メロキシカムの精製方法 Download PDFInfo
- Publication number
- JP4324812B2 JP4324812B2 JP2007293460A JP2007293460A JP4324812B2 JP 4324812 B2 JP4324812 B2 JP 4324812B2 JP 2007293460 A JP2007293460 A JP 2007293460A JP 2007293460 A JP2007293460 A JP 2007293460A JP 4324812 B2 JP4324812 B2 JP 4324812B2
- Authority
- JP
- Japan
- Prior art keywords
- meloxicam
- acid
- salt
- crude
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 title claims description 58
- 229960001929 meloxicam Drugs 0.000 title claims description 43
- 238000000034 method Methods 0.000 title claims description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 10
- -1 alcohol ester Chemical class 0.000 claims description 10
- 239000003125 aqueous solvent Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 6
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 5
- 239000012266 salt solution Substances 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 239000012296 anti-solvent Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 150000003141 primary amines Chemical class 0.000 claims description 2
- 239000012535 impurity Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 5
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- GUABFMPMKJGSBQ-UHFFFAOYSA-N 5-methyl-1,3-thiazol-2-amine Chemical compound CC1=CN=C(N)S1 GUABFMPMKJGSBQ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- HTZOXRHYFAORSJ-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-1$l^{6},2-benzothiazine-3-carboxylic acid Chemical compound C1=CC=C2S(=O)(=O)N(C)C(C(O)=O)=C(O)C2=C1 HTZOXRHYFAORSJ-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- YSMNECAIZNOYOW-UHFFFAOYSA-N 1,1-dioxo-2h-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound C1=CC=C2S(=O)(=O)NC(C(=O)N)=CC2=C1 YSMNECAIZNOYOW-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- QWTNANUGXZEPFQ-UHFFFAOYSA-N ethyl 4-hydroxy-2-methyl-1,1-dioxo-1$l^{6},2-benzothiazine-3-carboxylate Chemical compound C1=CC=C2S(=O)(=O)N(C)C(C(=O)OCC)=C(O)C2=C1 QWTNANUGXZEPFQ-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- XTUSEBKMEQERQV-UHFFFAOYSA-N propan-2-ol;hydrate Chemical compound O.CC(C)O XTUSEBKMEQERQV-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pain & Pain Management (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Detergent Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cosmetics (AREA)
Description
欧州特許公開第1462451号は、欧州特許公開第2482号に記載の有機溶媒の使用を回避するメロキシカム精製法を記載している。これは、水とNaOHの混合液中に粗製メロキシカムを溶解させ、続いて酸を添加して結晶形態のメロキシカムIを沈澱させることを含む。その間、温度は65℃から還流温度に保持される。
i.粗製メロキシカムを非水性溶媒中のアミンと接触させて、メロキシカムアミン塩を形成するステップと、
ii.前記メロキシカム塩を単離するステップと、
iii.前記メロキシカム塩を水性溶媒中に溶解させて塩溶液を形成するステップと、
iv.前記塩溶液に酸を加えて遊離メロキシカムを沈澱させるステップと
を含む方法を提供する。
実施例1
20.4gの4−ヒドロキシ−2−メチル−2H−1,2−ベンゾチアジン−3−カルボキシレート−1,1−ジオキシドエチルエステルと8.8gの2−アミノ−5−メチルチアゾールを300mlのo−キシレン中で24時間還流させ、反応副生物のエタノールを、4Aモレキュラーシーブを備えたソックスレー抽出装置で除去する。
Claims (14)
- 粗製メロキシカムからメロキシカムの形態Iを精製するための方法であって、
i.粗製メロキシカムを非水性溶媒中のアミンと接触させて、メロキシカム塩を形成するステップと、
ii.前記メロキシカム塩を単離するステップと、
iii.前記メロキシカム塩を水性溶媒中に溶解させて塩溶液を形成するステップと、
iv.前記塩溶液に酸を加えて遊離メロキシカムを沈澱させるステップと
を含む方法。 - 粗製メロキシカムが固体の形態である、請求項1に記載の方法。
- 粗製メロキシカムを第一級アミンと接触させる、請求項1に記載の方法。
- 粗製メロキシカムをN−メチルグルカミンまたはトリエチルアミンと接触させる、請求項1から3のいずれか一項に記載の方法。
- 非水性溶媒がアルコールを含む、請求項1から4のいずれか一項に記載の方法。
- アルコールがエタノールである、請求項5に記載の方法。
- アンチソルベントを加えてメロキシカム塩を沈澱させ、続いてろ過することによって前記メロキシカム塩を単離する、請求項1から6のいずれか一項に記載の方法。
- アンチソルベントが酸アルコールエステルである、請求項7に記載の方法。
- 酸アルコールエステルが酢酸アルキルである、請求項8に記載の方法。
- 水性溶媒が水である、請求項1から9のいずれか一項に記載の方法。
- 酸が酢酸、塩酸、硫酸またはリン酸である、請求項1から10のいずれか一項に記載の方法。
- 酸が酢酸である、請求項11に記載の方法。
- 塩溶液にカーボンも添加する、請求項1から12のいずれか一項に記載の方法。
- 沈澱したメロキシカムを続いてろ過し、洗浄し、乾燥する、請求項1から13のいずれか一項に記載の方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0623113A GB2443891B (en) | 2006-11-20 | 2006-11-20 | Process for the purification of meloxicam |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008127385A JP2008127385A (ja) | 2008-06-05 |
JP4324812B2 true JP4324812B2 (ja) | 2009-09-02 |
Family
ID=37605593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007293460A Expired - Fee Related JP4324812B2 (ja) | 2006-11-20 | 2007-11-12 | メロキシカムの精製方法 |
Country Status (22)
Country | Link |
---|---|
US (2) | US20080119647A1 (ja) |
EP (1) | EP1923392B1 (ja) |
JP (1) | JP4324812B2 (ja) |
AR (1) | AR063851A1 (ja) |
AT (1) | ATE420087T1 (ja) |
AU (1) | AU2007324354B2 (ja) |
BR (1) | BRPI0719029A2 (ja) |
CA (1) | CA2670464C (ja) |
CL (1) | CL2007003325A1 (ja) |
CY (1) | CY1109445T1 (ja) |
DE (1) | DE602007000466D1 (ja) |
DK (1) | DK1923392T3 (ja) |
ES (1) | ES2319337T3 (ja) |
GB (1) | GB2443891B (ja) |
MX (1) | MX2009005328A (ja) |
NZ (1) | NZ577199A (ja) |
PE (1) | PE20081118A1 (ja) |
PL (1) | PL1923392T3 (ja) |
PT (1) | PT1923392E (ja) |
SI (1) | SI1923392T1 (ja) |
UY (1) | UY30726A1 (ja) |
WO (1) | WO2008062151A1 (ja) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2756113A1 (de) * | 1977-12-16 | 1979-06-21 | Thomae Gmbh Dr K | Neue 4-hydroxy-2h-1,2-benzothiazin- 3-carboxamid-1,1-dioxide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
ES2223209B1 (es) * | 2001-12-11 | 2005-10-01 | Esteve Quimica, S.A. | Nuevas formas cristalinas del meloxicam y procedimientos para su preparacion e interconversion. |
CN1098265C (zh) * | 2001-08-24 | 2003-01-08 | 中国科学院大连化学物理研究所 | 一种美络昔康的精制工艺 |
DE10245882A1 (de) * | 2002-09-30 | 2004-04-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Modifikation der Verbindung 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazin-3-carboxamid-1,1-dioxid in Form eines kristallinen Essigsäure-Solvats und deren Verwendung als Arzneimittel |
US20060025408A1 (en) * | 2004-08-02 | 2006-02-02 | Sundaram Venkataraman | Process for the preparation of crystalline form-1 of 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide |
ITMI20041918A1 (it) * | 2004-10-11 | 2005-01-11 | A M S A Anonima Materie Sintetiche Affini Spa | Processo di purificazione di meloxicam |
HU227359B1 (en) * | 2004-12-18 | 2011-04-28 | Egis Gyogyszergyar Nyilvanosan Mikodi Ruszvunytarsasag | Process for producing meloxicam and meloxicam potassium salt of high purity |
-
2006
- 2006-11-20 GB GB0623113A patent/GB2443891B/en active Active
-
2007
- 2007-09-19 ES ES07079505T patent/ES2319337T3/es active Active
- 2007-09-19 SI SI200730025T patent/SI1923392T1/sl unknown
- 2007-09-19 AT AT07079505T patent/ATE420087T1/de active
- 2007-09-19 PL PL07079505T patent/PL1923392T3/pl unknown
- 2007-09-19 EP EP07079505A patent/EP1923392B1/en active Active
- 2007-09-19 PT PT07079505T patent/PT1923392E/pt unknown
- 2007-09-19 DK DK07079505T patent/DK1923392T3/da active
- 2007-09-19 DE DE602007000466T patent/DE602007000466D1/de active Active
- 2007-10-09 CA CA2670464A patent/CA2670464C/en active Active
- 2007-10-09 AU AU2007324354A patent/AU2007324354B2/en active Active
- 2007-10-09 MX MX2009005328A patent/MX2009005328A/es not_active Application Discontinuation
- 2007-10-09 BR BRPI0719029-8A patent/BRPI0719029A2/pt not_active IP Right Cessation
- 2007-10-09 WO PCT/GB2007/003824 patent/WO2008062151A1/en active Application Filing
- 2007-10-09 NZ NZ577199A patent/NZ577199A/en unknown
- 2007-11-12 JP JP2007293460A patent/JP4324812B2/ja not_active Expired - Fee Related
- 2007-11-15 US US11/940,619 patent/US20080119647A1/en not_active Abandoned
- 2007-11-16 AR ARP070105095A patent/AR063851A1/es unknown
- 2007-11-19 PE PE2007001609A patent/PE20081118A1/es not_active Application Discontinuation
- 2007-11-20 UY UY30726A patent/UY30726A1/es not_active Application Discontinuation
- 2007-11-20 CL CL200703325A patent/CL2007003325A1/es unknown
-
2009
- 2009-03-02 US US12/396,044 patent/US8008480B2/en active Active
- 2009-03-31 CY CY20091100382T patent/CY1109445T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE602007000466D1 (de) | 2009-02-26 |
EP1923392A1 (en) | 2008-05-21 |
US8008480B2 (en) | 2011-08-30 |
ES2319337T3 (es) | 2009-05-06 |
US20080119647A1 (en) | 2008-05-22 |
ATE420087T1 (de) | 2009-01-15 |
AU2007324354A1 (en) | 2008-05-29 |
GB2443891A (en) | 2008-05-21 |
CY1109445T1 (el) | 2014-08-13 |
CA2670464A1 (en) | 2008-05-29 |
EP1923392B1 (en) | 2009-01-07 |
GB2443891B (en) | 2009-04-08 |
JP2008127385A (ja) | 2008-06-05 |
PT1923392E (pt) | 2009-02-26 |
PE20081118A1 (es) | 2008-08-15 |
SI1923392T1 (sl) | 2009-06-30 |
UY30726A1 (es) | 2008-07-03 |
AR063851A1 (es) | 2009-02-25 |
AU2007324354B2 (en) | 2011-12-01 |
NZ577199A (en) | 2011-12-22 |
MX2009005328A (es) | 2009-06-08 |
US20090163707A1 (en) | 2009-06-25 |
BRPI0719029A2 (pt) | 2013-11-05 |
PL1923392T3 (pl) | 2009-07-31 |
CL2007003325A1 (es) | 2008-05-16 |
WO2008062151A1 (en) | 2008-05-29 |
GB0623113D0 (en) | 2006-12-27 |
DK1923392T3 (da) | 2009-05-04 |
CA2670464C (en) | 2012-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002350753B2 (en) | Novel crystalline forms of meloxicam and the preparation and interconversion methods thereof | |
WO2008045777A2 (en) | A process for the preparation of benzimidazole derivatives and their salts | |
CN102108077A (zh) | 制备右兰索拉唑的方法 | |
CN110637009B (zh) | 用于制备4-甲氧基吡咯衍生物的中间体的方法 | |
JP2006511561A (ja) | 結晶性セフジニル塩 | |
US20060089502A1 (en) | Ziprasidone process | |
JP2013519655A (ja) | エソメプラゾールナトリウムのナトリウム塩の調製方法 | |
JP2008524197A5 (ja) | ||
JP5329812B2 (ja) | 高純度メロキシカム及びメロキシカムカリウム塩の製法 | |
JP4324812B2 (ja) | メロキシカムの精製方法 | |
US7045618B2 (en) | Cefpodixime proxetil | |
KR101032600B1 (ko) | 고순도 레바미피드의 제조방법 | |
JP2007238596A (ja) | アミノ酸の二塩酸塩の生成のための直接的なプロセス | |
JP2008105970A (ja) | ジヒドロキノリン誘導体の製造方法及びその中間体 | |
JP6670744B2 (ja) | ヒオデオキシコール酸ナトリウム(NaHDC)の多形形態およびその調製方法 | |
US8198455B2 (en) | Process for the preparation of dexlansoprazole | |
US20120165527A1 (en) | process for the preparation of pure paliperidone | |
JPH11292873A (ja) | キノロンカルボン酸誘導体の製造方法およびその中間体 | |
WO2006010978A1 (en) | Cefdinir polymorphic forms, and imidazole salt | |
ES2201936B1 (es) | Procedimiento para la sintesis de pantoprazol e intermedios. | |
US20100093804A1 (en) | novel crystalline form of lansoprazole | |
JP5414163B2 (ja) | 5−{4−[2−(5−エチル−2−ピリジル)エトキシ]ベンジル}チアゾリジン−2,4−ジオン塩酸塩の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090410 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20090410 |
|
TRDD | Decision of grant or rejection written | ||
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20090430 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090507 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090526 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120619 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120619 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130619 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |